Shares of ImmuPharma plc (LON:IMM - Get Free Report) fell 10.6% during mid-day trading on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.18 ($0.15). 9,444,195 shares were traded during trading, an increase of 11% from the average session volume of 8,504,196 shares. The stock had previously closed at GBX 12.50 ($0.17).
ImmuPharma Price Performance
The firm has a 50 day simple moving average of GBX 4.28 and a 200-day simple moving average of GBX 3.27. The company has a market cap of £56.23 million, a price-to-earnings ratio of -1,264.38 and a beta of 1.53.
ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
(
Get Free Report)
ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.
While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
